Chromadex Corp Stock Price, News & Analysis

Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.

ChromaDex Corp. (NASDAQ: CDXC), transitioning to the name Niagen Bioscience, Inc. with a new Nasdaq ticker symbol NAGE, generates a steady flow of news centered on NAD+ science and healthy aging. As the self-described global authority on nicotinamide adenine dinucleotide (NAD+), the company regularly issues updates on its Niagen ingredient, Tru Niagen supplement brand, and pharmaceutical-grade Niagen IV and injection products.

News for CDXC often includes financial results and outlooks, where ChromaDex reports quarterly and annual net sales, gross margins, net income, and cash flow metrics, along with commentary on trends in Tru Niagen and Niagen ingredient sales. These releases may also discuss expectations for future revenue growth, margin performance, and planned investments in research, development, and marketing.

Investors can also expect corporate and investor relations announcements, such as participation in healthcare and growth company conferences, investor summits, and panel discussions on longevity and supplementation. These events typically feature company management presenting ChromaDex’s strategy, financial performance, and updates on its NAD+ research and product pipeline.

Another key category of news involves product and partnership developments. ChromaDex has announced the expansion of Niagen IV and related pharmaceutical-grade Niagen products across wellness clinic networks, as well as collaborations where Niagen serves as a hero ingredient in third‑party longevity supplements. The company also highlights recognition in industry lists and awards related to health products and business impact.

Finally, ChromaDex issues scientific and regulatory updates, including information about FDA designations for nicotinamide riboside in rare disease indications and progress toward regulatory milestones. For anyone tracking CDXC, or its successor symbol NAGE, this news feed offers a consolidated view of the company’s financial performance, clinical and regulatory progress, commercial expansion, and branding evolution around Niagen and NAD+ science.